abstract: OBJECTIVE: @entity914 is a complex illness for which optimal treatment is not well established. Results of the first controlled, relapse-prevention study of @entity16864 once-monthly injectable ( @entity7302 monthly) in @entity914 are presented. METHOD: The study was conducted between September 20, 2010, and October 22, 2013. @entity1 with @entity914 (confirmed by the Structured Clinical Interview for DSM-IV @entity74 ) experiencing acute exacerbation of @entity716 and @entity308 / @entity162 were stabilized with @entity7302 monthly as monotherapy or as adjunctive therapy to mood stabilizers or antidepressants and randomly assigned (1:1) to @entity7302 monthly or placebo in a 15-month, double-blind, relapse-prevention phase. Randomization was stratified by administration as monotherapy or adjunctive therapy and by study center. The primary endpoint was time to relapse. RESULTS: 334 @entity1 were evaluated. @entity7302 monthly significantly delayed time to relapse for @entity716 , @entity308 , and @entity162 compared with placebo (P < .001, log-rank test). Relapse risk was 2.49 times greater for placebo (hazard ratio = 2.49; 95% CI, 1.55 to 3.99; P < .001, Cox proportional hazards model). Overall relapse rates were 33.5% for placebo and 15.2% for @entity7302 monthly. For monotherapy, relapse risk was 3.38 times greater with placebo (P = .002), and for adjunctive treatment it was 2.03 times greater with placebo (P = .021). @entity7302 monthly was superior to placebo in maintaining functioning as measured by the Personal and Social Performance scale (P = .014, mixed-model repeated-measures analysis). The most common adverse events (placebo, @entity7302 monthly) were increased weight (4.7%, 8.5%), @entity22 (7.1%, 4.9%), @entity914 (5.9%, 3.0%), @entity10 (3.5%, 5.5%), and @entity11266 (3.5%, 5.5%). Incidence of any extrapyramidal-related adverse event was 7.1% for placebo and 8.5% for @entity7302 monthly. CONCLUSIONS: @entity7302 monthly as monotherapy or adjunctive therapy significantly delayed @entity716 , @entity308 , and/or manic relapses; reduced their risk; and better maintained functioning in @entity1 with @entity914 . Results support the value of maintenance treatment with @entity7302 monthly in @entity914 . TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01193153.

title: @entity16864 once-monthly reduces risk of relapse of XXXX , @entity308 , and @entity162 and maintains functioning in a double-blind, randomized study of @entity914 .

entities_list: @entity7302 :: ('MESH:C079150', 'Chemical') :: ['paliperidone', 'Paliperidone']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['manic symptoms']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive']

entities_list: @entity11266 :: ('MESH:D009304', 'Disease') :: ['nasopharyngitis']

entities_list: @entity914 :: ('MESH:D011618', 'Disease') :: ['Schizoaffective disorder', 'schizoaffective disorder']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Axis I Disorders']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity16864 :: ('MESH:C548956', 'Chemical') :: ['paliperidone palmitate']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']

answer: @entity716 :: (MESH:D011605,Disease) :: ['psychotic']


abstract: A method for determination chemical @entity26 demand (COD) assisted by use of ultrasound has been successfully evaluated for the first time. The method uses instrumentation simpler and cheaper and, in some instances, safer than that used by previous methods for the same purpose. The new device used for sonication is an all-glass cylindrical sonotrode that can be introduced directly into the reaction mixture. Use of this device enables more efficient interaction between sample and ultrasonic energy. The optimized experimental conditions are high ultrasonic power (55% amplitude, 0.9-second pulses each second), high @entity8316 concentration (>60%), and a sonication time of 2 min. Under these conditions the method has limitations similar to those of the official COD method with regard to the type of organic compound. It works adequately with easily oxidized organic matter ( @entity5244 and @entity413 ) and other organic compounds difficult to oxidize by conventional methods (e.g. @entity3971 and @entity1543 ) but the COD values obtained with volatile compounds and difficult organic matter are poor. @entity2865 is tolerated up to a concentration of 7000 mg L(-1) without any masking agent. Gasification of the sample is recommended to improve results; use of air and @entity3503 resulted in no significant differences - bubbling with air during sonication resulted in COD values for certified materials and real wastewater samples statistically identical with the certified COD values and those obtained by the classic (open reflux) method. The use of ultrasound energy for COD determination thus seems to be an interesting and promising alternative to conventional oxidation methods used for the same purpose.

title: Ultrasound-assisted method for determination of chemical XXXX demand.

entities_list: @entity8316 :: ('MESH:C033158', 'Chemical') :: ['sulfuric acid']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity5244 :: ('MESH:C032279', 'Chemical') :: ['potassium hydrogen phthalate']

entities_list: @entity2865 :: ('CHEBI:17996', 'Chemical') :: ['Chloride']

entities_list: @entity1543 :: ('MESH:D019342', 'Chemical') :: ['acetic acid']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['dextrose']

answer: @entity26 :: (MESH:D010100,Chemical) :: ['oxygen']


abstract: The aim of this study was to investigate the effect of orally administered, slow-release, @entity594 tablets on the circadian rhythm of blood pressure and heart rate, in hospital @entity1 with clinical diagnosis of @entity101 validated by a chronobiologic inferential statistic method. A group of 14 @entity1 (nine @entity1 and five @entity1 , 47 to 71 years old) with clinical diagnosis of "essential @entity101 " underwent automatic blood pressure and heart rate monitoring in a hospital room for 48 hours. Measurements were taken every 15 min by an oscillometric instrument with automatically inflated cuff. The @entity1 received no treatment during the two proceeding weeks and the first day of the study. On the second day, slow-release @entity594 tablets were administered, one at 10 a.m. and one at 10 p.m. A highly significant circadian rhythm was documented for systolic and diastolic blood pressure, mean arterial pressure and heart rate, both in basal conditions and after @entity594 . Blood pressure mesors were higher than reference standards in basal conditions, and were lowered (average decrease = 20 mmHg for systolic and 9 mmHg for diastolic mesor) by @entity594 . A significant, though minor, elevation of heart rate mesor (from 70 to 75 b.p.m.) was also noted during treatment. The circadian amplitudes of blood pressure and heart rate did not differ significantly before and during treatment. In conclusion, the circadian rhythm of blood pressure is still present with the same amplitude after slow-release @entity594 , but is set at a lower pressure level. Heart rate rhythm is also preserved, with only a minor elevation of its mesor.

title: Slow-release @entity594 : effect on the circadian rhythm of blood pressure in essential XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity594 :: ('MESH:D009543', 'Chemical') :: ['nifedipine']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: BACKGROUND: Ring @entity320 and @entity1539 is extremely rare and often has adverse histology. This @entity5 may cause raised intraocular pressure. METHODS: A review of four cases of @entity320 with insidious presentations seen in the ocular oncology service over a 12 month period. RESULTS: All four @entity1 presented with unilateral @entity1347 and @entity726 . The misdiagnoses of the causes of the @entity726 included @entity5513 from previous @entity130 ( @entity1 1); iridocorneal endothelial (ICE) syndrome supported by endothelial specular microscopy ( @entity1 2 and 3); and melanocytoma on ciliary body biopsy ( @entity1 4). Two @entity1 were treated by several cyclodiode ciliary body ablation treatments and the other two underwent trabeculectomies and Molteno tubes. Two of the four @entity1 have since died from their disease. CONCLUSION: The ophthalmologist should re-evaluate the diagnosis in @entity1 with @entity1347 and refractory @entity726 . Endothelial specular microscopy and biopsy of the suspicious lesion may give misleading reassurance. The potential presence of an @entity2184 must always be considered.

title: Ring XXXX --a rare cause of @entity726 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['angle recession']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['anterior segment abnormalities']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma', 'ipsilateral glaucoma', 'refractory glaucoma']

entities_list: @entity2184 :: ('MESH:C536494', 'Disease') :: ['anterior uveal melanoma']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma of the ciliary body', 'ring melanomas']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['blunt trauma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: @entity4600 ( @entity4601 ; 22:6n-3) is the major @entity844 in the @entity3633 of photoreceptor cells. The supply of preformed @entity4601 in milk may play an important role in early @entity1 visual development. We examined the effect of adding dietary @entity4601 from yolk or fish oil on its accretion in the retina of newborn piglets fed artificially for 2 wk. @entity4601 -enriched eggs from hens fed rapeseed oil and two fish oils with a high or low ratio of @entity7784 ( @entity8393 ; 20:5n-3) to @entity4601 were used. The basic (conventional) formula contained (% by wt of total @entity1718 ) 17% @entity4722 (18:2n-6) and 1.3% @entity7461 (18:3n-3). The yolk-enriched formula also contained 0.5% @entity1426 (AA; 20:4n-6) and 0.4% @entity4601 . The fish-oil-enriched formulas contained either 0.3% @entity8393 and 0.2% @entity4601 (from salmon oil) or < 0.1% @entity8393 and 0.3% @entity4601 (low- @entity8393 fish oil used at a low concentration), or 0.1% AA, 0.3% @entity8393 , and 0.9% @entity4601 (low- @entity8393 fish oil used at a high concentration). The low- @entity8393 fish oil used at a low concentration can supply the @entity4601 required without increasing the @entity8393 status but only the yolk-enriched formula allowed the artificially reared piglets to attain the same AA status in blood lipids as with sow milk feeding. The @entity4601 concentration plateaued in the retina when it reached 7.5% by wt of total @entity1718 in plasma phospholipids. Yolk phospholipids and fish oils are equally potent sources for supplying the highest retinal @entity4601 concentration, which was found to be 41.7% by wt of total @entity1718 in @entity3633 (compared with 35% without supplementation). Inclusion of 0.2-0.3% @entity4601 ensures maximal @entity4601 accretion in the retina but cosupplementation with AA is necessary to achieve the status with maternal feeding in blood lipids and to prevent any possible imbalance between n-6 and n-3 @entity1718 .

title: @entity4600 concentrations in retinal phospholipids of piglets fed an @entity1 formula enriched with long-chain polyunsaturated fatty acids: effects of egg phospholipids and fish oils with different ratios of XXXX to @entity4600 .

entities_list: @entity7784 :: ('MESH:D015118', 'Chemical') :: ['eicosapentaenoic acid']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity4600 :: ('CHEBI:28125', 'Chemical') :: ['Docosahexaenoic acid']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity3633 :: ('MESH:C483858', 'Chemical') :: ['phosphatidylethanolamine']

entities_list: @entity7461 :: ('MESH:D017962', 'Chemical') :: ['alpha-linolenic acid']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity4722 :: ('MESH:D019787', 'Chemical') :: ['linoleic acid']

answer: @entity7784 :: (MESH:D015118,Chemical) :: ['eicosapentaenoic acid']


abstract: OBJECTIVE: To characterize the immune reaction in SD @entity35 exposed to @entity4965 ( @entity4966 ) and to identify the gene expression profiles involved in skin after @entity4966 exposure. METHODS: Fifteen percent of @entity4966 was injected intradermally into the @entity35 back (100 microL/120 g) at intervals of 7 days. Whole blood was collected 24 h after the fifth or seventh intradermic administration of @entity4966 . The percentages of @entity11264 + and CD8+ of T lymphocytes were measured by a flow cytometer. The concentrations of @entity3692 and @entity12718 in the serum were semi-quantified by ELISA. Total RNAs of skin samples at 3 h or 24 h after the seventh dose of @entity4966 in SD @entity35 were extracted, and gene expression profiles of these tissues were analyszed by @entity35 toxicology U34 array of Affymetrix. RESULTS: Obvious decline of @entity11264 + in T lymphocytes was observed in the @entity4966 -administer group. No significant concentration differences in @entity3692 and @entity12718 were found between @entity4966 -treated and control @entity35 . @entity21679 and Mel were significantly up regulated in skin tissue 24 h after @entity4966 exposure. The expression regulation of immune response factors was as active as proteins associated with lipid metabolism and synthesis process in these skin samples of SD @entity35 exposed to @entity4966 . CONCLUSION: T-helper type 1 cells mediate immune response can not be elicited in @entity4966 -treated SD @entity35 , but certain @entity1200 can be induced.

title: Immune responses to @entity4965 and skin gene expression profiles in XXXX .

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune disorder']

entities_list: @entity4965 :: ('MESH:D014241', 'Chemical') :: ['trichloroethylene']

answer: @entity35 :: (10116,Species) :: ['Sprague Dawley rats']


abstract: This article aims to analyze the frequency and clinical characteristics of @entity1897 ( @entity1897 ) in @entity1 with @entity1252 ( @entity1252 ).A total of 4924 @entity1252 @entity1 admitted to the Peking Union Medical College Hospital, Beijing, China, from January 1995 to September 2013 were included in this retrospective analysis. The individuals designated as control @entity1 were selected from the pool of @entity1252 @entity1 without @entity1897 using the systematic sampling method of 1:2 during the same time.The prevalence of @entity1897 ( @entity1897 ) in @entity1252 @entity1 was 1.5% (73/4924). Seventy-nine cases of @entity1897 affected 73 @entity1 and 6 of these @entity1 (8.2%) presented with 2 types of @entity1897 . Among the 7 types of @entity1897 , @entity305 was the most frequent and was diagnosed in 47 cases (59.5%); the remaining @entity1 suffered from @entity4216 (13.9%), @entity129 (12.7%), @entity1737 (10.1%), @entity4148 (2.5%), or acute inflammatory demyelinating @entity8954 (1.3%). Five @entity1 developed @entity1897 before the onset of @entity1252 (3 out of 5 @entity1 had @entity1737 ). The most common @entity1897 -related symptoms were @entity1737 and @entity1183 (50.6%), followed by @entity158 in affected regions (35.9%). @entity1897 symptoms were relieved in a majority of the @entity1 (76.7%) after treatment. Compared with non- @entity1897 @entity1 , @entity1 with @entity1897 had a higher frequency of @entity221 (65.8% vs 45.9%, P<0.01), mucocutaneous involvement (73.9% vs 36.3%, P<0.01), @entity625 (42.5% vs 28.1%, P<0.05), @entity5442 (17.8% vs 5.5%, P<0.01), and central nervous system involvement (38.4% vs 21.9%, P<0.05) as well as being positive for the anti-Sm antibody (31.4% vs 18.8%), immunoglobulin G (IgG) elevation (53.6% vs 37.1%, P<0.01), and reduction in complement 3 (54.8% vs 36.9%, P<0.05). A statistically significant difference was found between the Systemic Lupus @entity66 Activity Index scores in @entity1897 @entity1 compared with the non- @entity1897 @entity1 (P<0.05). Multivariate logistic regression showed that the only risk factor for @entity1897 was IgG elevation (odds ratio=2.553, 1.224-5.327, P=0.012).The prevalence of @entity1897 in @entity1252 occurs more frequently in @entity1 with an active form of the disease. IgG elevation is a risk factor for @entity1897 and should be assessed in these @entity1 . Young female @entity1 with @entity1737 should be closely monitored for the development of @entity1252 .

title: XXXX due to @entity1252 in china.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial neuropathy']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Erythematosus Disease']

entities_list: @entity8954 :: ('MESH:D011129', 'Disease') :: ['polyradiculoneuropathy']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia', 'myasthenia gravis']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['SLE-associated PN', 'PN', 'SLE-PN', 'peripheral neuropathy']

entities_list: @entity4148 :: ('MESH:D001342', 'Disease') :: ['autonomic neuropathy']

entities_list: @entity4216 :: ('MESH:D020422', 'Disease') :: ['mononeuropathy']

answer: @entity1897 :: (MESH:D010523,Disease) :: ['Peripheral neuropathies']


abstract: PURPOSE: @entity189 in situ ( @entity2735 ) is an uncommon @entity5 that is poorly described in the published literature and is often under-recognized in the clinical setting. This short case series reports some challenges associated with the recognition and management of this disease. METHODS: A retrospective chart review was done over a 12-year period of @entity1 presenting with @entity5 to the Johns Hopkins Hospital. Four @entity1 were identified with @entity2735 of the anterior urethra, and their demographic and clinical data were recorded. RESULTS: Three @entity1 presented with meatal lesions that were initially treated as infectious/inflammatory diseases before diagnoses of @entity5 were determined following lesion biopsy. The fourth @entity1 presented with painless @entity811 and had a cystoscopy and biopsy of urethral @entity1127 . All @entity1 were treated surgically by sequential distal urethrectomy and various reconstructive procedures. Concurrent lymph node dissections were undertaken in two @entity1 who had clinical or radiologic evidence of @entity3329 . One @entity1 had persistent disease even after aggressive urethral resection, and he succumbed to his illness 2  years later. CONCLUSION: This is the largest series of urethral @entity2735 , a disease with potentially serious consequences. A high index of suspicion should be maintained when evaluating and managing these @entity1 .

title: XXXX in situ: recognition and management.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3329 :: ('MESH:D008206', 'Disease') :: ['lymphadenopathy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['urethral cancer', 'malignancy']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['Urethral carcinoma']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

answer: @entity189 :: (MESH:D002277,Disease) :: ['Urethral carcinoma']


abstract: INTRODUCTION: In Germany a new and unique remuneration system for @entity146 and psychosomatic stationary treatments (PEPP system) was introduced in 2013 on an optional basis. From 2015 it will be mandatory for @entity146 and psychosomatic facilities. The introduction of the PEPP system brings up different questions regarding the possible incentives of the new remuneration system and its effects on the supply of @entity146 and psychosomatic treatments. To conduct these necessary analyses a reliable database is needed. MATERIAL AND METHODS: The goal of the project "Indicators of @entity1 care in Psychiatric and Psychosomatic Facilities" (VIPP project) is to gather a representative database which reflects the situation of day-to-day @entity1 care performed by German @entity146 and psychosomatic facilities. The   21 data set represents the basis of this database which will be complemented by other data sources (i.e., financial statements and other economic data). A number of more than 100,000 cases per year has already been exceeded. These case data were provided by a wide range of @entity146 hospitals, departments and universities that participate in this project. The dataset is anonymised and by pooling the data it is not possible to identify the cases of a specific clinic. @entity1 receive a web-based access and have the possibility to analyse the data independently. RESULTS: Using the examples of coding accuracy and rehospitalisation rates the variety as well as the enormous potential of this database can be demonstrated. DISCUSSION: On the base of the VIPP database valid @entity1 care indicators can be identified and cross-sectional analyses can be conducted. From such results key data on health economic strategies can be derived and the incentives, strengths and limitations of this constantly changing system can be identified.

title: [Indicators of XXXX care in Psychiatric and Psychosomatic Facilities (VIPP project)--a database project].

entities_list: @entity1 :: ('9606', 'Species') :: ['Participants', 'patient']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: Up to 70% of @entity1 with @entity43 are diagnosed in the advanced stage. The standard treatment for advanced @entity43 is a combination of debulking surgery and chemotherapy. The goal of surgery is to reduce the @entity5 burden as much as possible. The survival of @entity1 with no @entity66 post-surgery is superior to that of @entity1 with visible residual lesions. In order to minimize the probability that a @entity1 has @entity66 , several aggressive surgical techniques have been proposed, including the removal of all visible disease on the diaphragm, the colon and elsewhere in the abdomen. These techniques include diaphragm resection, splenectomy and peritonectomy. Neoadjuvant chemotherapy is used to treat @entity1 if it is expected that adequate debulking surgery is unlikely to be successful or if they are evaluated to be too ill to undergo an extensive and lengthy operation. Several multi-center prospective randomized studies have shown that @entity1 who are treated with neoadjuvant chemotherapy followed by surgery are more likely to achieve the status of no @entity66 than are @entity1 treated with surgery alone. Consequently, it has been proposed that neoadjuvant chemotherapy is justified in order to achieve a status of no @entity66 ; however, treatment with neoadjuvant chemotherapy has not yet been shown to result in better survival than treatment with primary debulking surgery. On the other hand, large retrospective single institute studies have shown clear survival benefit to @entity1 undergoing primary surgery with no @entity66 at the end of surgery. Although it is hard to compare prospective randomized studies to retrospective studies, they could not be ignored. The goal of treatment should be no @entity66 at the end of primary surgery. To achieve this goal, @entity1 with @entity43 should undergo a thorough evaluation prior to the decision on the right treatment. This evaluation should include imaging studies to assess the sites and size of @entity3 , age and performance status. Furthermore, the surgical competence of each center should be evaluated periodically and a decision should be made individually for each @entity1 and center. The aim of this review is to analyze the updated relevant data on the approach to advanced @entity43 , primary debulking ( @entity1480 ) versus neoadjuvant chemotherapy (NACT).

title: [Advanced @entity43 : primary debulking ( XXXX ) or neoadjuvant chemotherapy (NACT) - still a debate].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'advanced stage ovarian cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['intra-abdominal tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity1480 :: (MESH:C563184,Disease) :: ['PDS']


abstract: BACKGROUND: Our aim was to assess long-term results after less than total parathyroidectomy for @entity2742 in @entity7582 . METHODS: Of 1888 @entity1 undergoing operation at our institution for @entity459 between 1972 and 2001, 83 (4.4%) had @entity7582 . Outcome data were available for 79; 66 underwent subtotal parathyroidectomy, 55 (83%) of these with bilateral thymectomy. In 13 @entity1 , only grossly enlarged glands were resected (mean 1.1 per @entity1 ) as the syndrome of @entity7582 was not yet evident or the initial exploration was performed elsewhere. RESULTS: Follow-up has been 48 +/- 51 months (mean + SD). Intraoperative serum @entity461 assay decay in 20 @entity1 was suggestive of cure in 18 @entity1 , none of whom required reoperation. Nine @entity1 (11%) required reoperation (3 required reoperation twice) after a mean interval of 77 +/- 53 months. @entity512 resulted in a lesser reoperation rate than resection of grossly enlarged glands (7% vs 30%, P =.02). At the time of review, 63 @entity1 (80%) were normocalcemic, 10 (13%) @entity14645 (2 after unsuccessful delayed autograft), and 7% hypercalcemic (none after reoperation). By Kaplan-Meier analysis, the rate of surgical cure ( @entity1 who are nonhypercalcemic) is 60% and 51% at 10 and 15 years, respectively. CONCLUSION: @entity512 reduces the need for reoperation. Selective reoperation leads to long-lasting biochemic cure.

title: Long-term results of less than total parathyroidectomy for XXXX in @entity7582 .

entities_list: @entity7582 :: ('MESH:D018761', 'Disease') :: ['multiple endocrine neoplasia type 1']

entities_list: @entity459 :: ('MESH:D049950', 'Disease') :: ['primary hyperparathyroidism']

entities_list: @entity14645 :: ('MESH:C562689', 'Disease') :: ['hypocalcemic']

entities_list: @entity512 :: ('MESH:C567308', 'Disease') :: ['Subtotal parathyroidectomy']

entities_list: @entity2742 :: ('MESH:D006961', 'Disease') :: ['hyperparathyroidism']

answer: @entity2742 :: (MESH:D006961,Disease) :: ['hyperparathyroidism']


abstract: AIM: To describe glycaemia in both breastfeeding @entity1 and artificially feeding @entity1 with @entity164 1 @entity6 , and the changes in glycaemia induced by suckling. METHODS: A blinded continuous @entity413 monitor was applied for up to 6 days in eight breastfeeding and eight artificially feeding @entity1 with @entity2175 . @entity1 recorded @entity413 levels, @entity2690 dosages, oral intake and breastfeeding episodes. A standardized breakfast was consumed on 2 days. A third group (clinic controls) were identified from a historical database. RESULTS: @entity1735 intake tended to be higher in breastfeeding than artificially feeding @entity1 (P=0.09) despite similar @entity2690 requirements. Compared with breastfeeding @entity1 , the high blood @entity413 index and standard deviation of @entity413 were higher in artificially feeding @entity1 (P=0.02 and 0.06, respectively) and in the clinical control group (P=0.02 and 0.05, respectively). The low blood @entity413 index and hypoglycaemia were similar. After suckling, the low blood @entity413 index increased compared with before (P<0.01) and during (P <0.01) suckling. Hypoglycaemia (blood @entity413 <4.0 mmol/l) occurred within 3 h of suckling in 14% of suckling episodes, and was associated with time from last oral intake (P=0.04) and last rapid-acting @entity2690 (P=0.03). After a standardized breakfast, the area under the @entity413 curve was positive. In breastfeeding @entity1 the area under the @entity413 curve was positive if suckling was avoided for 1 h after eating and negative if suckling occurred within 30 min of eating. CONCLUSIONS: Breastfeeding @entity1 with @entity164 1 @entity6 had similar hypoglycaemia but lower @entity413 variability than artificially feeding @entity1 . Suckling reduced maternal @entity413 levels but did not cause hypoglycaemia in most episodes. This article is protected by copyright. All rights reserved.

title: Glycaemic behaviour during breastfeeding in XXXX with @entity164 1 @entity6 .

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['Type 1 diabetes 2-4 months postpartum']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['Carbohydrate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: Muscarinic agonist-induced parasympathomimetic effects, in vivo phosphoinositide hydrolysis and @entity410 were evaluated in wild-type and muscarinic M1-M5 receptor knockout @entity19 . The muscarinic agonist @entity5592 induced marked @entity2332 in all the knockout @entity19 , but the @entity2332 was reduced in M2 and to a lesser extent in M3 knockout @entity19 . @entity5592 -induced @entity400 was abolished only in the M2 knockout @entity19 . Muscarinic agonist-induced salivation was reduced to the greatest extent in M3 knockout @entity19 , to a lesser degree in M1 and M4 knockout @entity19 , and was not altered in M2 and M5 knockout @entity19 . Pupil diameter under basal conditions was increased only in the M3 knockout @entity19 . @entity2134 -induced increases in in vivo phosphoinositide hydrolysis were completely absent in hippocampus and cortex of M1 knockout @entity19 , but in vivo phosphoinositide hydrolysis was unaltered in the M2-M5 knockout @entity19 . A high dose of @entity2134 (300 mg/kg) caused @entity410 and lethality in wild-type and M2-M5 knockout @entity19 , but produced neither effect in the M1 knockout @entity19 . These data demonstrate a major role for M2 and M3 muscarinic receptor subtypes in mediating parasympathomimetic effects. Muscarinic M1 receptors activate phosphoinositide hydrolysis in cortex and hippocampus of @entity19 , consistent with the role of M1 receptors in cognition. Muscarinic M1 receptors appear to be the only muscarinic receptor subtype mediating @entity410 .

title: Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and XXXX -induced @entity410 activity.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity2134 :: ('MESH:D010862', 'Chemical') :: ['Pilocarpine', 'pilocarpine']

entities_list: @entity5592 :: ('MESH:D010095', 'Chemical') :: ['oxotremorine', 'Oxotremorine']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

answer: @entity2134 :: (MESH:D010862,Chemical) :: ['pilocarpine']


abstract: AIM: This study aimed to explore clinical and care-related factors associated with fulfilling @entity5 @entity1 ' preference for home @entity204 across four countries: Belgium (BE), The Netherlands (NL), Italy (IT), and Spain (ES). METHODS: A mortality follow-back study was undertaken from 2009 to 2011 via representative networks of general practitioners (GPs). The study included all @entity1 aged 18 and over who had died of @entity5 and whose home @entity204 preference and place of @entity204 were known by the GP. Factors associated with meeting home @entity204 preference were tested using multivariable logistic regressions. RESULTS: Among 2,048 deceased @entity1 , preferred and actual place of @entity204 was known in 42.6 percent of cases. Home @entity204 preference met ranged from 65.5 to 90.9 percent. Country-specific factors included older age in BE, and decision-making capacity and being female in the NL. GPs' provision of palliative care was positively associated with meeting home @entity204 preference. Odds ratios (ORs) were: BE: 9.9 (95 percent confidence interval [CI] 3.7-26.6); NL: 9.7 (2.4-39.9); and IT: 2.6 (1.2-5.5). ORs for Spain are not shown because a multivariate model was not performed. CONCLUSION: Those who develop policy to facilitate home @entity204 need to examine available resources for primary end-of-life care.

title: Factors associated with fulfilling the preference for dying at home among XXXX @entity1 : the role of general practitioners.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: We characterized susceptibilities and genotypes in a series of @entity796 isolates from five cases of @entity293 ( @entity293 ) to evaluate clonal shifts of @entity2893 resistance. In one case, a series of isolates showed different susceptibility patterns for @entity2888 but an identical genotype. In another case, genotypes varied among 4 @entity796 isolates from recurrent @entity293 over 9 months. Although the @entity1 had been treated with no antibiotic immediately before isolation, the susceptibility patterns for @entity2888 and @entity5505 varied. Further analysis in these two cases of outer membrane protein profiles showed that loss of OprD production resulted in reduced susceptibilities to @entity2888 in all of the @entity2893 -resistant isolates. Loss of OprD production was likely due to oprD gene inactivation in both of cases, since the @entity2893 -resistant isolates showed no cross resistance to @entity800 and @entity2755 compared with the @entity2893 -susceptible isolates. There was another case in which all isolates showed similar susceptibility patterns for @entity2888 and @entity5505 , and an identical genotype during the intermittent use of antibiotics over 5 months. In two cases, a single course of antibiotic therapy resulted in eradication of @entity796 . Our results suggest that clonal shifts of @entity2893 resistance in @entity796 may result from loss of OprD during antibiotic treatment. Therefore, it is important for clinicians to monitor susceptibilities to antibiotics, especially @entity2888 , in @entity796 isolated during therapy.

title: Characterization of XXXX isolates from @entity1 with @entity293 during antibiotic therapy.

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa', 'P. aeruginosa']

entities_list: @entity800 :: ('MESH:D015242', 'Chemical') :: ['levofloxacin']

entities_list: @entity2893 :: ('CHEBI:46765', 'Chemical') :: ['carbapenem']

entities_list: @entity2888 :: ('MESH:D015780', 'Chemical') :: ['carbapenems']

entities_list: @entity2755 :: ('MESH:D002701', 'Chemical') :: ['chloramphenicol']

entities_list: @entity5505 :: ('MESH:D002442', 'Chemical') :: ['ceftazidime']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infections', 'UTIs']

answer: @entity796 :: (287,Species) :: ['Pseudomonas aeruginosa']


abstract: Bacterial polyesters have attracted much attention as biodegradable biocompatible polymers. @entity13099 , a microbially produced thermoplastic, has similar material properties to @entity7502 . Its potential application as biodegradable and biocompatible plastics is well documented. However, due to high cost it is used mainly in biomaterials for medical applications. Materials with useful properties may result from blending bacterial @entity13100 ( @entity13100 ) with other polymers. In this paper, the compatibility of @entity13100 with starch for improved properties and cost reduction is discussed. The thermal and mechanical properties of the blended films were studied by means of thermogravimetry, differential scanning calorimetry and an automated material testing system. The results revealed that blend films had a single glass transition temperature for all the proportions of @entity13100 :starch tested. The nature of all combinations was found to be crystalline. The tensile strength was optimum for the @entity13100 :starch ratio of 0.7:0.3 (wt/wt). The variation in tensile strength, Young's modulus, extension needed to break, thermal stability, glass transition temperature, melting temperature, for the different proportions of @entity13100 :starch are discussed.

title: Preparation and characterization of biodegradable XXXX -starch blend films.

entities_list: @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene']

entities_list: @entity13100 :: ('CHEBI:53388', 'Chemical') :: ['polyhydroxybutyrate', 'PHB']

entities_list: @entity13099 :: ('MESH:C003182', 'Chemical') :: ['Poly-3-hydroxybutyrate']

answer: @entity13099 :: (MESH:C003182,Chemical) :: ['poly-3-hydroxybutyrate']


abstract: OBJECTIVES: To examine the relationship between body mass index (BMI) and @entity1486 (PSA) in Chinese @entity1 and to investigate whether this relationship was independent of other factors. METHODS: Cross-sectional analysis was in @entity1 aged 19 to 82 years old (N=12,964) who without @entity263 and had health examination between 2008 and 2013 in a clinical center in Xi'an, China. @entity28 and overweight were classified according to the WHO criterion. Mean PSA level was calculated by categories (normal weight, overweight, and @entity28 ) and age group ( <= 40, 41-59, >=  60 years old). The association between BMI and PSA was examined using multivariate regression models and stratified by age. RESULTS: The crude prevalence was 38.42% for overweight and 3.47% for @entity28 in the study population. Mean PSA level increased with age at each BMI category. BMI was negatively associated with PSA level at each age group, independent of fasting plasma @entity413 (FPG) and prostate volume. Per unit increase in BMI was associated with a decrease of PSA by 0.03 (P=0.05), 0.11(P < 0.001), and 0.15 (P < 0.001) in @entity1 aged  <= 40, between 41 to 59, and > 60 years old, respectively. CONCLUSIONS: Our results indicate that a higher BMI is associated with a lower level of PSA in healthy Chinese @entity1 across all age group, independent of prostate volume and FPG. With the current @entity28 , individual's BMI should be considered when PSA test is used to screen or diagnose @entity263 .

title: An inverse association of body mass index and XXXX in northwest @entity1 of China: a population-based analysis.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obesity epidemic', 'obesity']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity1486 :: (354,Gene) :: ['prostate-specific antigen']


abstract: 191 @entity1 with nonpalpable @entity0 were admitted to the Clinic of Surgery of the I. M. Sechenov 1st Medical Institute. The @entity5 were detected during a mass screening survey; none of the @entity1 had any complaints. Examination and palpation failed to detect any pathologic changes in 60.2% of females, while in 39.8%, bilateral mastopathia cystica was found. All @entity1 underwent sectoral resection with interstitial marking of @entity5 . The marking procedure is described. Morphological examination confirmed X-ray diagnosis in 83% of cases. Most @entity5 were localized, while incipient invasive features were revealed in 58.3%. Morphologically, such @entity5 may be considered early @entity5 . When diagnosis of @entity5 was confirmed by histological examination, radical mastectomy after the method of Patey was performed (68.9%). The end results of treatment are presented. Early diagnosis and effective therapy of @entity0 are determined by cooperation of X-ray, surgery and pathology department staff.

title: [Diagnosis and treatment of nonpalpable XXXX ].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignant tumor', 'tumors']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast tumors']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast tumors']


abstract: BACKGROUND AND AIM OF THE STUDY: When correctly seated in the aortic position, stentless valves are associated with a relatively low transvalvular gradient. This leads to regression of @entity4346 and long-term survival. The alleged complexity of @entity340 has led to a preference for stented/mechanical prostheses. Here, the use of a rigid instrument to prevent technical complications after @entity340 was investigated. METHODS: Aortic valve replacement was performed in 75 @entity1 (44 males, 31 females; mean age 72 years; range: 33-89 years) using the Toronto Stentless Porcine Valve (TSPV). Among @entity1 , 37% had coronary artery bypass grafting and 3% mitral valve replacement. Valve size was either 23-25 mm (65%) or 21 mm (35%) and determined by sinotubular junction diameter. A rigid instrument was designed that mimics actual valve shape and accounted for valve dimensional variations and asymmetries on a size-by-size basis. The instrument was used to mark the site of the inflow and outflow suture lines and to determine orientation of the muscle bar on the prosthetic valve. Intraoperative transesophageal echocardiography was used to monitor all @entity1 . RESULTS: The mean intraoperative mean systolic peak pressure gradient (all valves) was 18.35 +/- 9.41 mmHg; there were no paravalvular leaks. Among @entity1 , 22% had central trace @entity337 , and one @entity1 developed @entity177 that required hemodialysis. There were no cerebral vascular accidents/ @entity281 , but one perioperative @entity583 occurred. There were four postoperative deaths, but none was valve-related. CONCLUSION: Routine use of the instrument may avoid many risks during TSPV implantation. The device permits the surgeon to accommodate variation in the angle between the coronary ostia, as well as in the distance between these ostia and the native annulus.

title: The use of a rigid instrument prior to XXXX facilitates correct alignment of the prosthesis and native aortic valve apparatus.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['left ventricular hypertrophy']

entities_list: @entity337 :: ('MESH:D001022', 'Disease') :: ['aortic insufficiency']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['stentless valve implantation']

answer: @entity340 :: (MESH:D006349,Disease) :: ['stentless valve implantation']


abstract: Nine distinct alpha subunits of @entity6370 binding proteins (G-proteins) have now been identified by cDNA cloning. Each of these functions to allow transduction of information between hormone-activated receptors in the plasma membrane and effector systems which are either ion channels or enzymes which regulate the intracellular concentration of second messengers. As the individual G-proteins are highly similar in primary sequence, it is pertinent to ask what degree of specificity of interaction each of these display with the various receptors and effector systems. Specificity of tissue location defines that the rod and cone transducins (TD1 and @entity61688 , respectively) act as the coupling proteins between @entity1999 and cone opsins and their cyclic @entity377 phosphodiesterase effectors and that @entity67946 is the G-protein which tranduces signals from odorant receptors to adenylate cyclase in olfactory sensory neurones. However, many of the other identified G-proteins are co-expressed in a single tissue or cell. Whilst sensitivity to @entity857 -ribosylation catalysed by bacterial toxins from @entity7320 and @entity1838 has allowed a further subdivision of the G-protein family, this approach is limited as these toxins have multiple G-protein substrates. As the extreme C-terminus of the alpha subunit of each G-protein appears to be a key domain for the interactions of receptors and G-proteins we have generated a series of G-protein-selective antipeptide antisera against this region and then have used these antisera to attempt to interfere with receptor-G-protein coupling. With this approach we have been able to demonstrate that a delta opioid receptor-mediated inhibition of adenylate cyclase in @entity521 x @entity11 , @entity19 , cell membranes is transduced specifically by Gi2 and in the same cell that alpha 2 adrenergic inhibition of @entity141 currents is transduced by Go. Similar strategies are likely to be of universal significance, for example in the identification of the G-protein (Gp) which regulates the receptor-mediated activation of phosphoinositidase C. Methods to allow pharmacological manipulation of the levels of expression of various G-proteins in the membranes of cells are also discussed. Such approaches are also likely to assist in the identification of G-proteins of defined functions.

title: The role and specificity of XXXX binding proteins in receptor-effector coupling.

entities_list: @entity7320 :: ('520', 'Species') :: ['Bordetella pertussis']

entities_list: @entity6370 :: ('CHEBI:61292', 'Chemical') :: ['guanine nucleotide']

entities_list: @entity1838 :: ('666', 'Species') :: ['Vibrio cholerae']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma']

answer: @entity6370 :: (CHEBI:61292,Chemical) :: ['guanine nucleotide']


abstract: BACKGROUND: The probiotic microorganisms are live normal flora that provide nutritional benefits. When probiotic administered in adequate amounts, they also confer a health benefit on the host. Different mechanisms of probiotic effects include the following: stimulating the immune system, modifying the composition of normal intestinal flora and preventing the carcinogenic activity of fecal enzymes. In this study, direct effects of probiotic lactobacilli on @entity5 cells were investigated. METHODS: Supernatants and bacterial extracts of two standard @entity6329 species ( @entity9206 and @entity6329 ) were prepared and CaCo-2 cells were treated with them. Probiotic effects on cell proliferation, @entity39 , apoptosis, migration and invasion were assessed. RESULTS: The supernatants of Lactobacilli decreased cell proliferation and increased cell apoptosis, however, no significant effect on cell @entity39 was reported. In contrast, Lactobacilli extract, reduced cell proliferation and increased cell apoptosis. Lactobacilli extract also led to cell @entity39 . Furthermore, both supernatants and cell extracts of the probiotic agents resulted in decreased cells' migration and invasion. CONCLUSION: In this study, it was shown that Lactobacilli probiotics useful effects are not confined to the enhancement of the immune system; however, they effectively suppress the malignant phenotypes of @entity14 cells.

title: Effects of Probiotic @entity9206 and XXXX @entity6329 on @entity14 Cells Activity (CaCo-2).

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity6329 :: ('1582', 'Species') :: ['L. casei', 'Lactobacillus']

entities_list: @entity9206 :: ('1579', 'Species') :: ['L. acidophilus']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity6329 :: (1582,Species) :: ['Lactobacillus']


abstract: UNASSIGNED: @entity56 caused by 9kDa Lipid Transfer Proteins (9k- @entity63322 ), such as Pru p 3, have been widely investigated, whereas a possible contribution of components of 7kDa @entity63322 (7k- @entity63322 ) sub-family in triggering @entity56 has been overlooked so far. With the aim to investigate the contribution of 7k-LTPs to the @entity5419 , we have identified, isolated and characterised a @entity523 seed 7k- @entity63322 (Sola l 7k- @entity63322 ). The protein was purified by chromatographic separations, identified by direct protein sequencing and mass spectrometry and a molecular model was built. Functional evaluation of the allergen has been performed by skin testing. Sola l 7k- @entity63322 consists of 68 @entity1522 producing a molecular mass of 7045Da and displays 41% sequence identity with Pru p 3, the allergenic 9k- @entity63322 from peach. IgE antibodies specifically recognising Sola l 7k- @entity63322 were found within the population claiming @entity523 ingestion-related symptoms, but also in subjects tolerant on @entity523 exposure. A few subjects were mono-sensitised to Sola l 7k- @entity63322 , which is biologically active as shown by the positive skin test. In line with the immunological results, the molecular model shows structural similarities between the IgE binding regions of the two sub-families. Therefore, Sola l 7k- @entity63322 shares some structural and immunological features with Pru p 3, but it also displays individual features that could be responsible for mono-specific IgE binding. In conclusion, Sola l 7k- @entity63322 is a new identified allergenic @entity63322 , the description of which may contribute to the improvement of @entity566 diagnosis and to the formulation of a safe and personalised diet. In addition, to avoid current confusing classifications, a new nomenclature policy for @entity63322 sub-families is proposed in this paper. We now suggest that 7-kDa @entity63322 (so far named @entity63323 ) be renamed 7k- @entity63322 and 9-kDa @entity63322 (so far named @entity63322 ) be renamed 9k- @entity63322 .

title: Structural features, IgE binding and preliminary clinical findings of the 7kDa Lipid Transfer Protein from XXXX seeds.

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergies']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['Allergic reactions', 'allergic symptoms']

answer: @entity523 :: (4081,Species) :: ['tomato']


abstract: AIMS: Accumulating evidence suggests that @entity731 depends on persistent and @entity32 in the arterial walls. @entity20214 is reportedly involved in @entity65 and has been implicated as a pro- @entity32 regulator. Although some researchers have focused on @entity20214 as an @entity731 regulator, the mechanisms by which @entity20214 functions as a putative pro- @entity731 microRNA are largely unknown. This study aims to analyze @entity20214 's effects on @entity731 and to explore its mechanism. METHODS: @entity20214 's effects on @entity731 were observed along with the expression and activity levels of @entity21606 , @entity10433 and NF-kB though @entity20214 inhibition or overexpression. RESULTS: Highly expressions of @entity20214 in oxLDL-stimulated macrophages and @entity731 @entity19 were inversely correlated with @entity21606 expression. Ectopic @entity20214 overexpression significantly promoted inflammatory cytokine and chemokine production and @entity731 progression. We then observed @entity20214 's functional role in the @entity731 pathophysiological process in vivo and in vitro. The observation revealed that by enhancing @entity10433 and NF-kB signaling and facilitating immune @entity32 by targeting @entity21606 , @entity20214 plays a promotable role in @entity731 progression. CONCLUSIONS: @entity20214 works as a promoter in the @entity731 procession. Its mechanism may include enhancing @entity32 in @entity731 by increasing @entity10433 and NF-kB signaling via targeting @entity21606 .    2015 S. Karger AG, Basel.

title: @entity20214 Promotes @entity32 via Targeting XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['chronic inflammation', 'inflammation', 'inflammatory response']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis', 'atherosclerotic progression', 'atherosclerotic inflammation']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity21606 :: (12703(Tax:10090),Gene) :: ['SOCS1']


abstract: BACKGROUND: Perioperatory chemoradiotherapy (CRT) improves local control and survival in @entity1 with locally advanced @entity5 (LARC). The objective of the current study was to evaluate the addition of bevacizumab ( @entity1493 ) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging. METHODS: @entity1 (pts) were randomized to receive 5  weeks of radiotherapy 45  Gy/25 fractions with concurrent CAP 825  mg/m(2) twice daily 5  days per week and @entity1493 5  mg/kg once every 2  weeks (3 doses) (arm A), or the same schedule without @entity1493 (arm B). The primary end point was pathologic complete response (ypCR: ypT0N0). RESULTS: Ninety pts were included in arm A (44) or arm B (46). Grade 3-4 treatment-related @entity137 rates were 16% and 13%, respectively. All @entity1 but one (arm A) proceeded to surgery. The ypCR rate was 16% in arm A and 11% in arm B (p =0.54). Fifty-nine percent vs 39% of pts achieved T-downstaging (arm A vs arm B; p =0.04). Serial samples for biomarker analyses were obtained for 50 out of 90 randomized pts (arm A/B: 22/28). Plasma @entity877 ( @entity877 ) levels decreased in arm A and increased in arm B (p <0.05 at all time points). Decrease in @entity877 levels from baseline to day 57 was significantly associated with @entity5 downstaging (p =0.02). CONCLUSIONS: The addition of @entity1493 to CAP-based preoperative CRT has shown to be feasible in LARC. The association between decreasing @entity877 levels and @entity5 downstaging should be further validated in customized studies. TRIAL REGISTRY: Clinicaltrials.gov identifier NCT01043484. Trial registration date: 12/30/2009.

title: A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced XXXX : clinical and biological features.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'rectal cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: BACKGROUND: Fear and aggression are often reported among professionals working in locked @entity146 wards and also among the @entity1 in the same wards. Such situations often lead to coercive intervention. In order to prevent coercion, we need to understand what happens in dangerous situations and how @entity1 and professionals interpret them. RESEARCH QUESTIONS: What happens when dangerous situations occur in a ward? How do professionals and @entity1 interpret these situations and what is ethically at stake? RESEARCH DESIGN: @entity1 observation and interviews. @entity1 : A total of 12 @entity1 and 22 professionals participated. ETHICAL CONSIDERATIONS: This study has been accepted by the Regional Committee for Medical and Health Research Ethics in Norway. FINDINGS: (a) Both atmosphere and material surroundings were interweaved within dangerous situations, (b) the professionals applied stereotypes when interpreting dangerous situations and (c) the professionals and the @entity1 had different interpretations of what triggered dangerous situations. DISCUSSION: The discussion centres on how care ethics and a dialogical practice might contribute towards combating difficult situations and the ways in which change is an ongoing ethical process of becoming. CONCLUSION: The ethics of care and a dialogical approach are suggested as ethical frameworks for preventing fear, danger and aggression in @entity146 wards. Both frameworks can be understood as @entity1 -driven, including the relational and contextual perspectives. It means a shift from professionally driven processes to @entity1 -driven dialogue.

title: Fear, danger and aggression in a Norwegian locked XXXX ward: Dialogue and ethics of care as contributions to combating difficult situations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Participant', 'PARTICIPANTS']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

answer: @entity146 :: (MESH:D001523,Disease) :: ['psychiatric']


abstract: OBJECTIVES: To assess whether DCE-MRI pharmacokinetic (PK) parameters obtained before and during chemotherapy can predict pathological complete response (pCR) differently for different @entity0 groups. METHODS: Eighty-four @entity1 who received neoadjuvant chemotherapy for locally advanced @entity0 were retrospectively included. All @entity1 underwent two DCE-MRI examinations, one before ( @entity25277 ) and one during treatment (EX2). @entity5 were classified into different @entity0 groups, namely triple negative (TNBC), @entity1722 + and ER+/ @entity1722 -, and compared with the whole population (WP). PK parameters Ktrans and Ve were extracted using a two-compartment Tofts model. RESULTS: At @entity25277 , Ktrans predicted pCR for WP and TNBC. At EX2, maximum diameter (Dmax) predicted pCR for WP and ER+/ @entity1722 -. Both PK parameters predicted pCR in WP and TNBC and only Ktrans for the @entity1722 +. pCR was predicted from relative difference ( @entity25277   -   EX2)/ @entity25277 of Dmax and both PK parameters in the WP group and only for Ve in the TNBC group. No PK parameter could predict response for ER+/HER-. ROC comparison between WP and @entity0 groups showed higher but not statistically significant values for TNBC for the prediction of pCR CONCLUSIONS: Quantitative DCE-MRI can better predict pCR after neoadjuvant treatment for TNBC but not for the ER+/ @entity1722 - group. KEY POINTS:     DCE-MRI-derived pharmacokinetic parameters can predict response status of neoadjuvant chemotherapy treatment.     Ktrans can better predict pCR for the triple negative group.     No pharmacokinetic parameter could predict response for the ER+/ @entity1722 - group.

title: Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced XXXX : the impact of @entity0 subtypes on the diagnostic accuracy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumours']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: In this phase II, multicentre trial, @entity1 with @entity0 ( @entity0 ) were treated with a combination of @entity136 , @entity1259 and @entity1311 (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete responce (CR) and overall response rate of the GET combination in this @entity1 population. @entity1 with no prior treatment for @entity0 , and at least one bidimensionally measurable lesion received @entity136 1000 mg m(-2) intravenously (i.v.) over 30 min on days 1 and 4, followed by @entity1259 i.v. at 90 mg m(-2) on day 1, and @entity1311 175 mg m(-2) over 3 h on day 1, every 21 days, up to eight courses. From May 1999 to June 2000, 48 @entity1 were enrolled from seven Italian institutions. A total of 297 chemotherapy courses were administered with a median of six cycles @entity1 (-1) (range 1-8). Seven @entity1 (15%) obtained CR and 27 @entity1 (56%) had partial responce, for an overall response rate of 71% (95% CI: 58.3-83.7). After a median follow-up of 23.7 months (range 7.0-34.4), median progression-free survival was 10.5 months (95% CI: 9.2-11.7), and median overall survival 25.9 months. The main haematological @entity137 consisted of grade 3 or 4 @entity1398 that occurred in 62% of cycles (22% grade 4 and 40% grade 3). The GET combination is active and well tolerated as first-line chemotherapy for @entity0 .

title: Multicentric phase II trial of @entity136 plus XXXX plus @entity1311 as first-line chemotherapy in @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer', 'MBC']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity1259 :: (MESH:D015251,Chemical) :: ['epirubicin']


abstract: @entity6 and its complications constitute a major health problem in modern societies. The disease affects approximately 5% of the adult population in western countries. The underlying process of the @entity209 is a defect in @entity2690 secretion, @entity2690 action, or both. Weight reduction, calorie restriction and @entity1 education remain the cornerstones of the management of @entity164 2 @entity6 . When lifestyle modification fails to maintain adequate glycaemic control, @entity2690 or oral hypoglycemic agents are typically used to manage the disease. The currently available five classes of oral agents differ in mechanism and duration of action, the degree to which they lower blood @entity413 and their side-effect profile. For most of these antiglycaemic agents, there is a lack of evidence on the effects on long-term complications. Only @entity2449 has clearly proved that it can reduce mortality in @entity28 @entity1 with @entity164 2 @entity6 . @entity1 @entity2690 reduces acute and long-term mortality in @entity1 with CVD. Furthermore, intensive treatment either with @entity2690 or @entity4136 has proved that it can prevent microvascular complications in @entity164 2 @entity6 . Additional randomized controlled trails assessing hard clinical endpoints are needed to better inform @entity1 and enable physicians to establish optimal treatment strategies.

title: [Drug treatment of XXXX 2 @entity6 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Human']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'Diabetes mellitus']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disorder']

entities_list: @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: OBJECTIVE: The purpose of the current study was to investigate the effect of the dosing time on the pharmacokinetics of @entity3866 and the circadian rhythms of the metabolism enzymes in @entity5 -bearing @entity19 . METHODS: Female C57BL @entity19 were randomly assigned to six groups. @entity3866 was orally administrated to the @entity19 in each group at six different times of day. The plasma concentration of @entity3866 was determined through a high-performance liquid-chromatographic assay, and the total mRNA was extracted from liver tissues to determine the expression of the mRNA of the related drug metabolism enzymes by qRT-PCR. RESULTS: The results indicated that AUC0-24  h and MRT0-24  h were the lowest in the 20:00 group (P  <  0.01). T max of the 13 @entity3917 ( @entity3917 ), 17 @entity3917 and 21 @entity3917 groups was higher than that of the 1 @entity3917 and 5 @entity3917 groups (P  <  0.01). CL of the light-phase groups was lower than that of the dark-phase groups (P  <  0.01). The peak value of C max appeared in the 5 @entity3917 group (P  <  0.01). The mRNA levels of @entity43340 , @entity67686 and @entity21570 were generally higher during the afternoon and the dark phase. CONCLUSION: Circadian rhythm plays a critical role in the pharmacokinetics of @entity3866 in @entity19 , and the mechanisms may be attributed to gene expression rhythms of drug-metabolizing enzymes in liver tissues.

title: Chronopharmacokinetics of @entity3866 and Circadian Rhythms of Related Metabolic Enzymes in Lewis Tumor-Bearing XXXX .

entities_list: @entity3917 :: ('MESH:D020795', 'Disease') :: ['hour after light onset', 'HALO']

entities_list: @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib', 'Erlotinib']

answer: @entity19 :: (10090,Species) :: ['Mice']


abstract: UNASSIGNED: 171 Background: Community Care of North Carolina (CCNC) initiated an innovative @entity910 ( @entity910 ) program in the 1990s to improve primary care in Medicaid-insured populations. CCNC has been successful in improving @entity565 , @entity6 , and cardiovascular outcomes, but has not been evaluated in the context of @entity5 care. We sought to determine whether @entity910 enrollment was associated with guideline-concordant surveillance and follow-up care among @entity0 survivors. METHODS: Using state @entity5 registry records matched to Medicaid claims, we identified @entity1 ages 18-64 diagnosed with stage 0, I, or II @entity0 from 2003-2007 and tracked their CCNC enrollment. Using published American Society for Clinical Oncology @entity0 survivorship guidelines to define our outcomes, we employed multivariate logistic regressions to examine correlates of receipt of surveillance mammogram and at least two physical exams within 15 months post-diagnosis. RESULTS: In total, 840 @entity1 were included in our sample. Approximately half were enrolled in a CCNC @entity910 during the study period, 38% were enrolled for more than 7 months post-diagnosis. Enrollment in a @entity910 for at least 7 months post-diagnosis was strongly associated with receiving guideline-recommended surveillance mammogram (p<0.01) and at least 2 physical exams (p<0.01) within 15 months post-diagnosis. CONCLUSIONS: Results suggest that @entity910 enrollment is associated with higher @entity0 survivorship care among @entity1 insured by Medicaid. Given the growing population of @entity5 survivors and increased emphasis on primary care @entity910 , more research is needed to explore how medical homes can enhance and ensure the provision of guideline-recommended care during @entity5 survivorship.

title: Guideline-concordant surveillance and follow-up care among low-income XXXX with @entity0 : The role of primary care medical homes.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['quality breast cancer', 'breast cancer']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['MH', 'medical home']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: The level of agreement between two blood pressure (BP) reading methods, auscultatory vs oscillometric, was examined using a @entity349 sphygmomanometer and an electronic device in @entity1 and adolescents with different levels of @entity28 . The readings were compared to see their impact on the diagnosis of pre- @entity101 / @entity101 . METHODS: Blood pressure readings were taken in @entity1 with @entity28 (body mass index >=  95th percentile) and severe @entity28 (>= 120% 95th percentile). We used the Bland-Altman analysis and Intraclass Correlation Coefficient to determine the agreement between measurements. RESULTS: The @entity349 sphygmomanometer readings were lower than those obtained with the electronic device for both systolic and diastolic BP (p=0.01 and 0.001, respectively). The average systolic and diastolic BP differences between the oscillometric vs first @entity349 reading were 4.2/10.2mm Hg, respectively. A large difference was observed between the BP measurement methods. The ICC showed regular to moderate reliability for the systolic BP (.595) but poor for the diastolic BP (.330). Screening using the first of three @entity349 measurements showed that 10.4% of the @entity1 and adolescents had BPs within the pre- @entity101 / @entity101 range. This was reduced to 5.2% when the three @entity349 readings were averaged. CONCLUSIONS: Large discrepancies were observed in both the systolic and diastolic BP. These differences are not clinically acceptable to consider the two instrument interchangeable. The electronic device readings were higher and they overestimated the diagnosis of @entity101 .

title: Comparison of auscultatory and oscillometric BP readings in @entity1 with XXXX and the effect on diagnosing arterial @entity101 .

entities_list: @entity349 :: ('MESH:D008628', 'Chemical') :: ['mercury']

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: PURPOSE: To describe a bilateral, central, oval corneal opacity not resembling any known @entity22911 . METHODS: Ophthalmic examination, corneal topography, and pachymetry. RESULTS: A 30-year-old @entity1 presented @entity227 . Biomicroscopic examination revealed bilateral, centrally located, oval, diffuse opacification of the anterior corneal stroma. Corneal topography showed slightly paracentral corneal flattening and irregular @entity940 in both eyes. Pachymetry indicated thinning of the central @entity735 . No evidence of @entity262 was found. Family members had no @entity2687 . CONCLUSIONS: This unusual keratopathy closely resembles climatic proteoglycan stromal keratopathy. However, it is not clear whether the condition should be described as a @entity3986 or @entity528 .

title: Bilateral central anterior stromal @entity3986 or XXXX ?

entities_list: @entity940 :: ('MESH:D001251', 'Disease') :: ['astigmatism']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['complaining of blurred vision']

entities_list: @entity3986 :: ('MESH:D009136', 'Disease') :: ['dystrophy']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['cornea in the left eye']

entities_list: @entity22911 :: ('MESH:C535472', 'Disease') :: ['corneal degeneration or dystrophy']

entities_list: @entity2687 :: ('MESH:D003316', 'Disease') :: ['corneal abnormalities']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['degeneration']

answer: @entity528 :: (MESH:D009410,Disease) :: ['degeneration']


abstract: OBJECTIVES/HYPOTHESIS: This study was designed to evaluate hearing preservation after gamma knife radiosurgery (GKRS) and to determine the relation between hearing preservation and cochlear radiation dose in @entity1 with a sporadic @entity5513 ( @entity5513 ). METHODS: Prospective study involving @entity1 suffering from @entity5513 who received GKRS from June 2003 until November 2007. Pure tone and speech audiometry were conducted before and after GKRS. The thresholds at pure tone audiometry were taken as a measure of hearing. Pure tone average (PTA) was defined as the mean threshold at 0.5 kHz, 1.0 kHz, 2.0 kHz, and 4.0 kHz. Hearing was classified according to the 2003 consensus meeting in Tokyo. Stereotactic surgery was performed using a Leksell 4C Gamma Knife (Elekta, Stockholm, Sweden). RESULTS: A total of 69 @entity1 were included in the study. Mean @entity5 size was 17 mm. Mean marginal dose at the @entity5 was 11.0 Gy (range, 9.3 Gy-12.3 Gy), mean maximal dose was 19.7 Gy (range, 16 Gy-25.5 Gy). Mean maximal dose at the cochlea was 10.27 Gy (range, 3.1 Gy-16.1 Gy), and mean minimal dose at the cochlea was 2.6 Gy (range, 0.9 Gy-7.4 Gy). Mean PTA before GKRS was 43 dB (standard deviation [SD] 20 dB), mean PTA after GKRS was 63 dB (SD 30 dB). Mean interval between pre-GKRS audiometry and GKRS was 8.0 months. Between GKRS and post-GKRS audiometry, mean interval was 14.2 months. Hearing was considered to be preserved (max +1 class, Tokyo classification) in 52 (75%) of 69 @entity1 . However, only 32 @entity1 had class A, B, or C (serviceable hearing) before GKRS. Within this group, only 13 @entity1 (41%) had a hearing class A, B, or C after GKRS. A significant relation was found between the maximal cochlear dose and the difference in PTA before and after GKRS. CONCLUSIONS: Hearing preservation is correlated to the maximal radiation dose at the cochlea. The purpose of developing GKRS techniques was to avoid collateral damage in healthy tissues. This study emphasizes the need for exact radiation planning to reduce the cochlear radiation dose if the hearing is to be preserved. Laryngoscope, 2009.

title: Gamma knife radiosurgery for XXXX : results of hearing preservation in relation to the cochlear radiation dose.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['vestibular schwannoma', 'VS']

answer: @entity5513 :: (MESH:D009464,Disease) :: ['vestibular schwannomas']


abstract: OBJECTIVE: To assess the efficacy of a @entity1206 + @entity632 combination in terms of response rate and time to progression in @entity1 with locally advanced or metastatic @entity0 . METHODS: @entity1206 (25 mg/m2) and @entity632 (25 mg/m2) were administered intravenously in a rapid injection on days 1 and 8 every 21 days. Initially, 3 courses of @entity1206 + @entity632 were given. @entity1 with responding or stable disease received 6 more courses to a maximum of 9 courses. RESULT: Twenty-nine @entity1 were entered into the study and 27 eligible @entity1 were considered evaluable for response. Median age was 45 years (range 33 to 63). Overall response rate was 66.67% (18/27) ( @entity49459 , PR = 13). Median time to progression was 7.8 months (range 4 to 16) and the median survival time was 25.9 months. Median follow-up time was 8.5 months (range 1.5 to 25). @entity137 was generally moderate. Hematologic complication was the dose limiting @entity137 . WHO grade III/IV @entity1398 was observed in 18.5%/3.7% of @entity1 . The major non-hematologic @entity137 were @entity390 and @entity3527 . Grade @entity1209 was observed in 7.4% and grade III/IV @entity3527 in 3.7%/3.7% of @entity1 . No toxic deaths were observed. CONCLUSION: The present @entity1206 + @entity632 combination was highly effective and generally well tolerated in cases of @entity0 . Further studies are required.

title: Combination of @entity1206 + @entity632 in XXXX .

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'advanced breast cancer']

entities_list: @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine', 'Vinorelbine']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['III nausea/vomiting']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity3527 :: ('MESH:D010689', 'Disease') :: ['phlebitis']

answer: @entity0 :: (MESH:D001943,Disease) :: ['advanced breast cancer']


abstract: Ischemic forearm exercise invariably causes muscle cramps and @entity158 in @entity1 with @entity154 . We investigated an alternative diagnostic exercise test that may be better tolerated. Nine @entity1 with @entity9847 , one with the partial glycolytic defect @entity16055 mutase deficiency, and nine matched, healthy subjects performed the classic @entity63 forearm protocol and an identical protocol without @entity63 . Blood was sampled in the median cubital vein of the exercised arm. Plasma @entity880 level increased similarly in healthy subjects during @entity63 (Delta5.1 +/- 0.7mmol L(-1)) and non- @entity63 ( @entity21316 .4 +/- 0.3) tests and decreased similarly in @entity9847 @entity1 (Delta-0.10 +/- 0.02 vs Delta-0.40 +/- 0.10mmol L(-1)). Postexercise peak @entity880 to @entity3265 ratios clearly separated @entity1 and healthy controls in @entity63 ( @entity9847 , 4 +/- 2 [range, 1-12]; partial glycolytic defect @entity16055 mutase deficiency, 6; healthy, 33 +/- 4 [range, 17-56]) and non- @entity63 ( @entity9847 , 5 +/- 1 [range, 1-10]; partial glycolytic defect @entity16055 mutase deficiency, 5; healthy, 42 +/- 3 [range, 35-56]) protocols. Similar differences in @entity880 to @entity3265 ratio between @entity1 and healthy subjects were observed in two other work protocols using intermittent handgrip contraction at 50% and static handgrip exercise at 30% of maximal @entity2472 force. All @entity1 developed @entity158 and cramps during the @entity63 test, and four had to abort the test prematurely. No @entity1 experienced cramps in the non- @entity63 test, and all completed the test. The findings indicate that the diagnostic @entity63 forearm test for @entity74 should be replaced by an aerobic forearm test.

title: A nonischemic forearm exercise test for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['glycolytic defects']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity16055 :: ('CHEBI:61304', 'Chemical') :: ['phosphoglycerate']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity9847 :: ('MESH:D006012', 'Disease') :: ['McArdle disease', 'McArdle']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['glycolytic disorders']

entities_list: @entity2472 :: ('MESH:C536214', 'Disease') :: ['voluntary contraction']

answer: @entity9847 :: (MESH:D006012,Disease) :: ['McArdle disease']


abstract: BACKGROUND: @entity2339 dysregulation is associated with increased risk for suicidal behavior. However, it is not clear whether such dysregulation exists prior to or is a consequence of attempt. Studies also show an activation of inflammatory responses in suicidal behavior but often combine attempters with those with ideation. METHODS: The sample consisted of @entity146 inpatients, aged 15-30 years, admitted for suicide attempt (SA, n=38), inpatients admitted for suicidal ideation with no prior history of attempts (SI, n=40), and healthy controls (n=37). We compared SA, SI, and controls on hair @entity701 concentrations (HCC), which provides retrospective levels of @entity701 and thus prior to the attempt in SA. We also compared them on the expression of genes in the @entity2339 and inflammatory pathways previously implicated in suicidal behavior ( @entity4738 or @entity4738 , @entity45502 , @entity13784 , @entity1356 , @entity310 ); plasma @entity1851 (CRP); and cellular measures of @entity4738 ( @entity4738 ) sensitivity and stimulated production of @entity650 . RESULTS: We found lower HCC [b=-0.55, 95% CI (-0.96, -0.13), p=0.01, ES=-0.54] in first-time SA compared to SI and controls. In addition, SA showed lower @entity4738 or @entity4738 (a isoform) mRNA [b=-5.11, 95% CI (-10.9, 0.73), p=0.09, ES=-0.46], higher CRP [b=0.94, 95% CI (-0.004, 1.9), p=0.05, ES=0.60], and higher @entity310 mRNA [b=26.4, 95% CI (7.7, 45.2), p=0.006, ES=0.73]. CONCLUSIONS: This is the first study to differentiate youth who attempt suicide from those with suicidal ideation on HCC and to show that low HCC precedes suicide attempt. Suicide attempters also showed a distinct biological profile on several markers in both the @entity2339 and inflammatory pathways. Future longitudinal studies are needed to examine the ability of these biomarkers to predict suicidal behavior.

title: Blunted XXXX activity prior to suicide attempt and increased inflammation in attempters.

entities_list: @entity4738 :: ('2908', 'Gene') :: ['NR3C1', 'glucocorticoid receptor', 'GR']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['HPA axis', 'Hypothalamic-Pituitary-Adrenal (HPA) axis']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-Reactive Protein']

answer: @entity2339 :: (MESH:D007029,Disease) :: ['HPA axis']


abstract: RATIONALE: Dysregulation of noradrenergic and dopaminergic systems is involved in the pathology of @entity71 ( @entity71 ). Carbonic anhydrase (CA) has been reported to affect @entity1154 transmission in the central nervous system. OBJECTIVES: The aim of this study is to investigate the effect of CA inhibitors on the @entity2915 and impulsivity of the spontaneously @entity101 @entity35 (SHR), which is currently the best-validated animal model of @entity71 . METHODS: SHRs and @entity35 Kyoto @entity35 at 6 to 8  weeks of age were pretreated with intraperitoneal injections of @entity3791 and @entity11681 , both carbonic anhydrase inhibitors, before the behavior tests. The open-field locomotion test and the electro-foot shock aversive water drinking test were then applied to quantify their @entity2915 and impulsivity, respectively. The Morris water maze test, on the other hand, monitored their spatial learning. RESULTS: @entity3791 and @entity11681 significantly inhibited the @entity2915 of SHRs but had no effects in @entity35 Kyoto @entity35 . @entity3791 also inhibited the impulsivity of SHRs. Low doses of @entity3791 had the greater inhibitory effects on the @entity2915 and impulsivity, but did not impair the spatial learning of SHRs. CONCLUSIONS: This is the first study to show that carbonic anhydrase inhibitors can strain-specifically antagonize the @entity2915 and impulsivity of SHRs. Under a low dose of @entity3791 , there was no @entity73 in SHRs. Carbonic anhydrase inhibitors may be the novel drugs for treatment for @entity1 with @entity71 .

title: Inhibition of @entity2915 and impulsivity by carbonic anhydrase inhibitors in spontaneously XXXX @entity35 , an animal model of @entity71 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity3791 :: ('MESH:D000086', 'Chemical') :: ['acetazolamide', 'Acetazolamide']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD', 'attention deficit hyperactivity disorder']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognition impairment']

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyperactivity']

entities_list: @entity11681 :: ('MESH:D008704', 'Chemical') :: ['methazolamide']

entities_list: @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertensive']


abstract: UNASSIGNED: Stem cell-based therapies for repair and regeneration of different tissues are becoming more important in the treatment of several diseases. Adult stem cells currently symbolize the most available source of cell progenitors for tissue engineering and repair and can be harvested using minimally invasive procedures. Moreover, mesenchymal stem cells (MSCs), the most widely used stem cells in stem cell-based therapies, are multipotent progenitors, with capability to differentiate into cartilage, bone, connective, muscle, and adipose tissue. So far, bone marrow has been regarded as the main source of MSCs. To date, @entity1 adult adipose tissue may be the best suitable alternative source of MSCs. Adipose stem cells (ASCs) can be largely extracted from subcutaneous @entity1 adult adipose tissue. A large number of studies show that adipose tissue contains a biologically and clinically interesting heterogeneous cell population called @entity455 ( @entity455 ). The @entity455 may be employed directly or cultured for selection and expansion of an adherent population, so called adipose-derived stem cells (ASCs). In recent years, literature based on data related to @entity455 cells and ASCs has augmented considerably: These studies have demonstrated the efficacy and safety of @entity455 cells and ASCs in vivo in animal models. On the basis of these observations, in several countries, various clinical trials involving @entity455 cells and ASCs have been permitted. This review aims at summarizing data regarding either ASCs cellular biology or ASCs-based clinical trials and at discussing the possible future clinical translation of ASCs and their potentiality in cell-based tissue engineering.

title: XXXX Adipose Stem Cells: From Bench to Bed-Side.

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['stromal vascular fraction', 'SVF']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: UNASSIGNED: Comprehensive two-dimensional liquid chromatography (LC  *  LC) has been gaining popularity for the analysis of complex samples in a wide range of fields including metabolomics, environmental analysis, and food analysis. While LC  *  LC can provide greater chromatographic resolution than one-dimensional LC (1D-LC), overlapping peaks are often still present in separations of complex samples, a problem that can be alleviated by chemometric curve resolution techniques such as multivariate curve resolution-alternating least squares (MCR- @entity2655 ). MCR- @entity2655 has also been previously shown to assist in the quantitative analysis of LC x LC data by isolating pure analyte signals from background signals which are often present at higher levels in LC x LC compared to 1D-LC. In this work we present the analysis of a dataset from the LC  *  LC analyses of parsley, parsnip and celery samples for the presence and concentrations of 14 @entity21852 . Several MCR- @entity2655 implementations are compared for the analysis of LC  *  LC data. These implementations include analyzing the LC x LC chromatogram alone, analyzing the one-dimensional chromatogram alone, as well as two hybrid approaches that make use of both the first and second dimension chromatograms. Furthermore, we compared manual integration of resolved chromatograms versus a simple summation approach, using the resolved chromatographic peaks in both cases. It is found that manual integration of the resolved LC  *  LC chromatograms provides the best quantification as measured by the consistency between replicate injections. If the summation approach is desired for automation, the choice of MCR- @entity2655 implementation has a large effect on the precision of the analysis. Based on these results, the concentrations of the 14 @entity21852 are determined in the three apiaceous vegetable types by analyzing the LC  *  LC chromatograms with MCR- @entity2655 and manual integration for peak area determination. The concentrations of the analytes are found to vary greatly between samples, even within a single vegetable type.

title: Comparison of multivariate curve resolution strategies in quantitative LCxLC: Application to the quantification of XXXX in apiaceous vegetables.

entities_list: @entity21852 :: ('MESH:D011564', 'Chemical') :: ['furanocoumarins']

answer: @entity21852 :: (MESH:D011564,Chemical) :: ['furanocoumarins']


abstract: A hallmark of regulatory B cells is @entity688 production, hence their designation as @entity21019 cells. Little is known about the ability of self-antigens to induce @entity688 + B cells in @entity2743 ( @entity2743 ), @entity2621 ( @entity2621 ), or other @entity792 . Here we pulsed purified B cells from 12 @entity2621 @entity1 , 12 @entity2743 @entity1 , and 12 healthy donors with the thyroid self-antigen, @entity3745 (TG) and added the B cells back to the remaining peripheral blood mononuclear cells (PBMCs). This procedure induced @entity21019 -cell differentiation in @entity2743 . A similar tendency was observed in healthy donors, but not in cells from @entity1 with @entity2621 . In @entity2743 , B cells primed with TG induced @entity688 -producing CD4+ T cells. To assess the maximal frequency of inducible @entity688 + B cells in the three donor groups PBMCs were stimulated with @entity4515 / @entity1360 . The resulting @entity21019 -cell frequency was similar in the three groups and correlated with free T3 levels in @entity2743 @entity1 . @entity688 + B cells from both @entity1 groups displayed @entity2902 or @entity34705 more frequently than did those from healthy donors. B-cell expression of two surface marker combinations previously associated with regulatory B-cell functions, @entity11707 hiCD38hi and @entity2731 + @entity12910 +, did not differ between @entity1 and healthy donors. In conclusion, our findings indicate that @entity1669 is not associated with reduced frequency of @entity21019 cells. These results do not rule out regulatory B-cell dysfunction, however. The observed phenotypic differences between @entity688 + B cells from @entity1 and healthy donors are discussed.

title: Characterization of Regulatory B Cells in @entity2743 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease", 'GD']

entities_list: @entity2621 :: ('MESH:D050031', 'Disease') :: ['HT', "Hashimoto's thyroiditis"]

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroiditis']

entities_list: @entity1360 :: ('MESH:D015759', 'Chemical') :: ['ionomycin']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease']

answer: @entity2621 :: (MESH:D050031,Disease) :: ['Hashimoto's Thyroiditis']


abstract: PURPOSE: @entity47903 ( @entity47903 ) is a novel orally administered (p.o.) prodrug of @entity9989 . Because p.o. IPdR is being considered for clinical testing as a radiosensitizer in @entity1 with high-grade @entity11 , we performed this in vivo study of IPdR-mediated @entity137 and radiosensitization in a @entity1 @entity463 xenograft model, @entity8001 . METHODS AND MATERIALS: Groups of 8 or 9 athymic male @entity19 (6-8 weeks old) were implanted with s.c. @entity8001 xenograft @entity5 (4 x 10(6) cells) and then randomized to 10 treatment groups receiving increasing doses of p.o. IPdR (0, 100, 250, 500, and 1000 mg/kg/d) administered once daily (q.d.) x 14 days with or without radiotherapy (RT) (0 or 2 Gy/d x 4 days) on days 11-14 of IPdR treatment. @entity137 was determined by body weight measurements during and after IPdR treatment. @entity5 response was assessed by changes in @entity5 volumes. RESULTS: IPdR alone at doses of > or =500 mg/kg/d resulted in moderate inhibition of @entity5 growth. The combination of IPdR plus RT resulted in a significant IPdR dose-dependent @entity5 growth delay, with the maximum radiosensitization using > or =500 mg/kg/d. IPdR doses of 500 and 1000 mg/kg/d resulted in transient 5-15% body weight loss during treatment. CONCLUSIONS: In @entity8001 @entity1 @entity463 s.c. xenografts, p.o. IPdR given q.d. x 14 days and RT given 2 Gy/d x 4 days (days 11-14 of IPdR treatment) results in a significant @entity5 growth delay in an IPdR dose-dependent pattern. The use of p.o. IPdR plus RT holds promise for Phase I/II testing in @entity1 with high-grade @entity11 .

title: @entity47903 -mediated @entity137 and radiosensitization in XXXX @entity1 @entity463 xenografts.

entities_list: @entity9989 :: ('MESH:D007065', 'Chemical') :: ['5-iododeoxyuridine']

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Systemic toxicity', 'cytotoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'Tumor']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

entities_list: @entity47903 :: ('MESH:C045889', 'Chemical') :: ["5-iodo-2-pyrimidinone-2'-deoxyribose", 'IPdR']

answer: @entity8001 :: (641648,Gene) :: ['U87']


abstract: OBJECTIVE: Because stage IIIC corpus @entity5 is a heterogeneous substage, the outcomes of @entity1 with stage IIIC disease were assessed according to the extent of extrauterine disease. METHODS: From 1984 through 1993, 51 @entity1 with surgical stage IIIC corpus @entity5 were treated at our institution; 5 @entity1 had @entity5 with nonendometrioid histologic features and were excluded from the analyses. Of the 46 @entity1 with @entity4348 , 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)). The mean number of lymph nodes removed was 18 pelvic and 8 aortic nodes. Median follow-up for surviving @entity1 was 84 months. RESULTS: @entity1 with stage IIIC(0) @entity5 had a 5-year cause-specific survival (CSS) of 72% and a 5-year @entity1349 ( @entity1349 ) of 68%, and those with stage IIIC(ab) had a CSS of 33% and an @entity1349 of 25% (P < 0.01). Of the 22 @entity1 with stage IIIC(0) @entity5 , 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated. Relapse occurred in 7 (32%) @entity1 , with only 1 having an initial failure component outside the node-bearing areas (lung). Of the 24 @entity1 with @entity5 , 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated. We observed 16 recurrences (67%). Of the 14 @entity1 with known initial sites of failure, 9 had an extranodal failure component. CONCLUSION: Assessment of CSS, @entity1349 , and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus @entity5 includes two distinct and readily separable subgroups: (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these. Our results also suggest that different treatment strategies are needed for these subgroups.

title: Stage IIIC endometrioid corpus XXXX includes distinct subgroups.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'stage IIIC(ab) cancer', 'endometrioid cancer', 'tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4348 :: ('MESH:D018269', 'Disease') :: ['endometrioid carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['RFS', 'recurrence-free survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: Exercise echocardiography with image acquisition during treadmill exercise is the most common form of stress testing used in our department. The usual evaluation of @entity1 with @entity1121 consists of serial echocardiographic studies at rest. The purpose of this study was to evaluate intraventricular gradients during exercise echocardiography in @entity1 with a diagnosis of @entity1121 . We studied 13 @entity1 , 8 male, mean age 56 +/- 9 years Intraventricular gradients were measured using continuous wave Doppler; two evaluations were performed at rest: one in left lateral decubitus and the other in orthostatic position after one minute in this position. The @entity1 then underwent a treadmill exercise test using the modified Bruce protocol, during which intraventricular gradients were measured at peak exercise. Finally, a further measurement was taken in the first 90 seconds of the recovery period in left lateral decubitus. The intraventricular gradient in left lateral decubitus was 54 +/- 29 mmHg; in orthostatic position 69 +/- 30 mmHg (p < 0.001 versus gradient in left lateral decubitus); at peak exercise 109 +/- 47 mmHg (p < 0.001 versus gradient in orthostatic position); and during recovery in left lateral decubitus 78 +/- 33 mmHg (p < 0.001 versus gradient at peak exercise in orthostatic position). We conclude that intraventricular gradients increase significantly in orthostatic position and increase considerably during treadmill exercise testing. The gradients measured in the recovery period do not reflect what happens during effort or therefore during these @entity1 ' daily activities. This type of evaluation can help us to better understand the pathophysiology of @entity1 with a diagnosis of @entity1121 and to optimize treatment.

title: Evaluation of XXXX by exercise stress echocardiography. New methodology.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['hypertrophic obstructive cardiomyopathy']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['hypertrophic obstructive cardiomyopathy']


abstract: UNASSIGNED: Studies assessing the effect of bevacizumab ( @entity1493 ) on @entity0 outcome have shown different effects on progression-free and overall survival, suggesting that a subgroup of @entity1 may benefit from this treatment. Unfortunately, no biomarkers exist to identify these @entity1 . Here, we investigate whether single nucleotide polymorphisms (SNPs) in @entity7 pathway genes correlate with pathological complete response (pCR) in the neoadjuvant GeparQuinto trial. @entity1722 -negative @entity1 were randomized into treatment arms receiving either @entity1493 combined with standard chemotherapy or chemotherapy alone. In a pre-planned biomarker study, DNA was collected from 729 and 724 @entity1 , respectively from both treatment arms, and genotyped for 125 SNPs. Logistic regression assessed interaction between individual SNPs and both treatment arms to predict pCR. Five SNPs may be associated with a better response to @entity1493 , but none of them remained significant after correction for multiple testing. The two SNPs most strongly associated, @entity65563 and @entity24280 , were located upstream of the @entity7 promoter. Odds ratios for the homozygous common, heterozygous and homozygous rare @entity65563 genotypes were 2.36 (95%CI, 1.49-3.75), 1.20 (95%CI, 0.88-1.64) and 0.61 (95%CI, 0.34-1.12). Notably, some SNPs in @entity7 exhibited a more pronounced effect in the triple-negative subgroup. Several SNPs in @entity7 may be associated with improved pCR when receiving @entity1493 in the neoadjuvant setting. Although none of the observed effects survived correction for multiple testing, our observations are consistent with previous studies on @entity1493 efficacy in @entity0 . Further research is warranted to clarify the predictive value of these markers. This article is protected by copyright. All rights reserved.    2014 Wiley Periodicals, Inc.

title: Genetic variants in @entity7 pathway genes in neoadjuvant @entity0 XXXX receiving bevacizumab: Results from the randomized phase 3 GeparQuinto study.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity1 :: (9606,Species) :: ['patients']